Findings from a proof-of-concept study suggest that fecal microbiota transplantation may not be a suitable option for patients with active peripheral psoriatic arthritis but further investigation is still needed.
Findings from a small study suggest that rituximab-treated patients with depleted B cells may be able to mount a T cell-mediated immune response to COVID-19 vaccination, despite having an impaired antibody response.
Patients with rheumatic diseases who have stable disease remission or low disease activity might be able to reduce their biologic DMARD treatment without disease flare by spacing their doses, BIOPURE findings show.
Findings from the Euro-COVIMID study suggest that the seroprevalence and effects of SARS-CoV-2 infection in patients with rheumatic diseases are in line with those in the general population, and inflammation may be a risk factor for developing symptomatic COVID-19.
Individuals with COVID-19 have a high prevalence of lupus antigen positivity upon hospital admission, but this is not associated with an increased risk for venous thromboembolism or in-hospital mortality, French researchers report.
Patients with rheumatoid arthritis may derive better clinical outcomes from baricitinib than tofacitinib in the first 24 weeks of treatment, especially if they have previously received multiple biologic DMARDs, show real-world data.
Study findings presented at the online British Society for Rheumatology 2021 Annual Conference suggest that people with vasculitis have an elevated mortality risk during COVID-19 and influenza outbreaks.
A comparison of different composite measures suggests that PASDAS has the strongest ability to predict disease activity and treatment response in patients with oligoarticular or polyarticular psoriatic arthritis.
Less than half of patients with polymyalgia rheumatica are prescribed medications for osteoporosis, despite clinical guidelines recommending bone protection for those on long-term glucocorticoid treatment, research suggests.
Research presented at the online British Society for Rheumatology 2021 Annual Conference has identified predictors of adverse events in people with rheumatoid arthritis receiving treatment with methotrexate.
Real-world study results suggest that the majority of baricitinib-treated patients with rheumatoid arthritis remain on the JAK inhibitor after a year, with older age and female sex associated with treatment persistence.
A urate lowering treat-to-target approach combined with personalized advice can help the majority of patients with gout achieve satisfactory serum urate levels, but some modifiable barriers to target fulfillment still exist, Norwegian researchers report.